1.. Introduction {#s1}
================

Extracellular nucleotides play important roles in cardiovascular physiology, and in vascular tissues prolonged nucleotide signalling has been implicated in the pathophysiology of restenosis, diabetic microvascular disease, and hypertension.^[@CVQ249C1]^ Purine/pyrimidine nucleotide release can have different effects on vascular tone depending on the site of release and cell type(s) with which the nucleotide interacts.^[@CVQ249C1]^ Nucleotides released from endothelial cells after shear stress and/or hypoxia can cause smooth muscle relaxation;^[@CVQ249C1],[@CVQ249C2]^ contrastingly, nucleotide release from sympathetic neuronal inputs act directly on vascular smooth muscle causing contraction.^[@CVQ249C1],[@CVQ249C3],[@CVQ249C4]^

Nucleotide signalling is mediated through different classes of receptor, including the ionotropic P2X and metabotropic P2Y receptor families.^[@CVQ249C5]^ Vascular smooth muscle cell contractile responses are mediated through the P2X~1~ subtype and several P2Y subtypes (i.e. P2Y~2,4,6~). P2X~1~-receptors cause a rapid influx of Ca^2+^ to initiate smooth muscle contraction. The G protein-coupled receptors (GPCRs) P2Y~2~, P2Y~4~, and P2Y~6~ couple with Gα~q/11~ proteins to activate phospholipase C (PLC), generating inositol 1,4,5-trisphosphate (IP~3~) and diacylglycerol. This initiates the mobilization of intracellular Ca^2+^ stores, activation of protein kinase C, and induces contraction.^[@CVQ249C1],[@CVQ249C5]^ Both P2X- and P2Y-mediated pathways are known to contribute significantly to the control of vascular tone.^[@CVQ249C3],[@CVQ249C6],[@CVQ249C7]^

Considering the potentially important roles that P2Y-receptors may play in the aetiology of vascular disease, very little is currently known regarding the regulation of their signalling in vascular smooth muscle. P2Y-receptors, like most GPCRs, are known to undergo desensitization,^[@CVQ249C8],[@CVQ249C9]^ a process which can prevent prolonged/inappropriate receptor-mediated signalling.^[@CVQ249C10]^ Desensitization of agonist-occupied GPCRs is usually initiated by the recruitment of G protein-coupled receptor kinases (GRKs), which phosphorylate key serine/threonine residues within the third intracellular (i3) loop and/or C-terminal tail of the GPCR.^[@CVQ249C10]^ GRK-mediated phosphorylation promotes the binding of non-visual arrestins (arrestin2 and/or arrestin3), which sterically inhibit GPCR-G protein interactions, and promote receptor internalization.^[@CVQ249C10],[@CVQ249C11]^ Of the seven GRK isoenzymes (GRK1--7) and four arrestin isoforms (arrestin1--4) expressed in mammals, GRK2, GRK3, GRK5, and GRK6, and arrestin2 (β-arrestin-1) and arrestin3 (β-arrestin-2) are commonly reported to be ubiquitously expressed.^[@CVQ249C10]^ Here, we have characterized the desensitization and resensitization of P2Y-receptor responses in mesenteric arterial smooth muscle cells (MSMCs), a widely documented model of systemic resistance arteries.^[@CVQ249C12]^ Furthermore, we have combined confocal imaging with biochemical and molecular biological manipulation of individual GRK and arrestin subtypes to identify their roles in the regulation of endogenous P2Y-receptor-stimulated PLC signalling and contraction of MSMCs.

2.. Methods {#s2}
===========

2.1. Isolation and culture of MSMCs {#s2a}
-----------------------------------

Adult male Wistar rats were killed by cervical dislocation, a method approved under the United Kingdom Animals (Scientific Procedures) Act 1986. The investigation also conforms to the Guide for Care and Use of Laboratory Animals US (NIH Publication No. 85-23, revised 1996). Smooth muscle cells were isolated from small branches of mesenteric artery by enzymatic dissociation as previously described.^[@CVQ249C12]^ Smooth muscle cells were separated by gentle trituration in 231 medium (Cascade Biologics, Nottingham, UK), supplemented with smooth muscle growth supplement, 100 IU/mL penicillin, 100 µg/mL streptomycin, and 2.5 µg/mL amphotericin B. Cells plated onto coverslips were maintained at 37°C and 5% CO~2~ in humidified conditions.

2.2. Myography {#s2b}
--------------

Contractile force recordings were made from 2 to 4 mm ring segments of third-order mesenteric arteries mounted in a Mulvany-Halpern wire myograph (JP Trading, Denmark). The bath solution contained (mM): NaCl 134, KCl 6, MgCl~2~ 1, CaCl~2~ 1.8, glucose 4, mannitol 6, HEPES 10, pH 7.4. NaCl was reduced to 81 mM and replaced with 60 mM K^+^ for the high K^+^ solution. All bathing solutions contained [l]{.smallcaps}-NAME (20 µM) to prevent endogenous nitric oxide production. Solutions and drugs were added directly to the organ bath, maintained at 37°C.

2.3. Relative contributions of P2Y receptors to MSMC Ca^2+^ signalling {#s2c}
----------------------------------------------------------------------

MSMCs were plated into 96-well multiplates. Monolayers (∼90% confluency) were loaded with the Ca^2+^-sensitive dye Fluo4-AM (3 µM) at room temperature for 60 min. Selective P2Y~2/4/6~-receptor agonists (Tocris, Bristol, UK) were added and changes in intracellular Ca^2+^ levels (\[Ca^2+^\]~i~) were determined as the relative change in fluorescence using a NovoStar imaging system (BMG Labtech, Aylesbury, UK).

2.4. Single cell confocal imaging {#s2d}
---------------------------------

UTP-stimulated PLC activity was determined in MSMCs transfected (24--48 h after isolation) with the pleckstrin-homology domain of phospholipase Cδ1 tagged with enhanced green fluorescent protein (eGFP-PH, 0.5 µg an extensively characterized IP~3~ biosensor^[@CVQ249C13]^) using confocal imaging exactly as previously described^[@CVQ249C14]^ (see [Supplementary material online](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq249/DC1)). Changes in cytosolic eGFP-PH fluorescence are displayed as the fluorescence emission (*F*)/initial basal fluorescence (*F*~0~) (*F/F*~0~). Additional Ca^2+^ experiments in the absence of eGFP-PH were conducted using Fluo-4-AM (3 µM, 60 min) and imaged as for eGFP.

2.5. Manipulating cellular GRK and arrestin levels {#s2e}
--------------------------------------------------

To assess the role that GRKs play in the regulation of P2Y-receptor signalling, MSMCs were co-transfected with eGFP-PH (0.5 µg), and the following dominant-negative, catalytically inactive GRK mutants: ^D110A,K220R^GRK2, ^D110A,K220R^GRK3, ^K215R^GRK5, ^K215R^GRK6 (0.5 µg),^[@CVQ249C14]^ or negative control plasmid (pcDNA3). Additionally, GRK2 expression was depleted using anti-GRK2 small interfering (si)RNA (10 nM) \[with non-targeting siRNA as negative-control (NC)\].^[@CVQ249C14]^ Our previous data demonstrated that co-transfection rates are \>90%,^[@CVQ249C14]^ therefore we have assumed that eGFP-expressing cells are successfully co-transfected. To examine the role that arrestins play in the regulation of P2Y-receptor signalling, MSMCs were transfected with anti-arrestin2 (5′-GCCACUGACUCGGCUACAAtt-3′; 100 nM), anti-arrestin3 (5′-GCCUUCUGUGCCAAAUCUAtt-3′; 100 nM), or NC siRNA (100 nM) (Applied Biosystems, UK). Arrestin depletion was assessed 48 h after nucleofection (Lonza AG, Cologne, Germany) by immunoblotting using an anti-arrestin2 antibody (A1CT). Arrestin expression was quantified using the GeneGnome image analysis system (Syngene, Cambridge, UK). For signalling studies, MSMCs were transfected using Lipofectamine2000 (Invitrogen, Paisley, UK) according to manufacturer\'s instructions and PLC activity assessed as described above.

2.6. Manipulating cellular P2Y receptor levels {#s2f}
----------------------------------------------

An siRNA approach was also applied to delineate the respective roles of P2Y~2~- and P2Y~4~-receptors in UTP-mediated signalling. MSMCs were transfected with differing concentrations of anti-P2Y~2~ (5′-GAACUGACACUGUGAGGAAtt-3′), or anti-P2Y~4~ (5′-CGUCUACUUCAGUUCGGCAtt-3′) siRNAs. To validate the siRNAs and to quantify P2Y~2~/P2Y~4~ knockdown, rat aortic smooth muscle cells were nucleofected and after 48 h lysed, mRNA isolated and transcribed into cDNA, prior to PCR amplification using a LightCycler instrument (Roche Applied Science, Burgess Hill, UK). Data are presented as Δ*C*~T~ values (calculated as *C*~T~ (scrambled siRNA-transfected cells)−*C*~T~ (anti-P2Y siRNA-transfected cells)). A more detailed method is provided in the accompanying [Supplementary Material](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq249/DC1).

2.7. Data and statistical analysis {#s2g}
----------------------------------

Data presented are from cells obtained from at least three separate preparations, expressed as means ± SEM. Data were analysed using one-way ANOVA as indicated, with appropriate *post hoc* testing (GraphPad Prism, San Diego, CA, USA).

3.. Results {#s3}
===========

3.1. Characterization of UTP-mediated contractions in mesenteric arteries {#s3a}
-------------------------------------------------------------------------

Concentration-dependent contractions of third-order mesenteric arteries (*Figure [1](#CVQ249F1){ref-type="fig"}A* and *B*) were induced by UTP addition, with maximal contraction seen at UTP concentrations ≥50 µM (EC~50~ 28 µM). Repeated addition of maximal UTP (100 µM, 5 min) concentrations, interspersed by 5 min wash periods produced robust arterial contractions with little evidence of tachyphylaxis (data not shown). These findings are consistent with those previously obtained for H~1~ histamine receptor-mediated Ca^2+^ responses,^[@CVQ249C15]^ where desensitization is masked by the presence of significant cell/tissue receptor reserve with respect to the observed response. To uncover any potential loss of UTP-induced contractile responsiveness, an amended protocol was applied where arteries were challenged with an approximate EC~50~ concentration of UTP (30 µM) for 5 min before (*R*~1~) and after (*R*~2~) the addition of a maximal UTP concentration (*R*~max~ = 100 µM, 5 min). Arteries were washed for 5 min between *R*~1~ and *R*~max~, and for 2--15 min between *R*~max~ and *R*~2~ agonist challenges. Reduced *R*~2~/*R*~1~ ratios are interpreted as an index of receptor/tissue desensitization.^[@CVQ249C14],[@CVQ249C15]^ *R*~2~ contractile responses compared with *R*~1~ were dramatically reduced (by ∼80%) following *R*~max~ exposure when the inter-*R*~max~/*R*~2~ delay was 2 min (*Figure [1](#CVQ249F1){ref-type="fig"}E*); extending the inter-*R*~max~/*R*~2~ wash period revealed a time-dependent resensitization of UTP-induced contractions with the *R*~1~/*R*~2~ ratio returning to ∼1 after 12--15 min (*Figure [1](#CVQ249F1){ref-type="fig"}C--E*). Figure 1Characterization of UTP-stimulated contractions of third-order mesenteric arteries. (*A*) Representative trace showing K^+^-induced contraction followed by washout and concentration-dependent UTP (0--100 µM)-stimulated contractions (*B*) Cumulative concentration-dependent UTP-stimulated arterial contraction data shown as means ± SEM for arterial preparations from at least four animals. (*C*--*E*) Desensitization protocol: arteries were exposed to 30 µM UTP (*R*~1~, for 1 min) challenge, followed by 5 min washout, maximal UTP (*R*~max~ = 100 µM, 1 min) challenge, followed by a variable period of 2--15 min washout before a further 30 µM UTP (*R*~2~, 1 min) exposure. Representative traces from single arteries with either a 5 min (*C*) or 15 min (*D*) *R*~max~-to-*R*~2~ washout period are shown. (*E*) Time-course of resensitization of the contractile response to UTP expressed as a percent change in *R*~2~ relative to *R*~1~ (means ± SEM for arterial preparations from at least four animals).

3.2. Characterization of UTP-mediated Ca^2+^ signalling in isolated MSMC {#s3b}
------------------------------------------------------------------------

Vascular smooth muscle cells are known to express several UTP-responsive (types 2/4/6) P2Y-receptors,^[@CVQ249C1]^ although it has not been conclusively determined which receptors contribute to UTP-stimulated Ca^2+^ signals, particularly in mesenteric smooth muscle. Therefore, various P2Y~2~-, P2Y~4~- and P2Y~6~-selective agonists were utilized to characterize the P2Y-receptor subtypes present in our preparation. The P2Y~2~-selective agonist 2-thio-UTP was more potent \[pEC~50~ (M) = 6.56\], but less efficacious than UTP \[pEC~50~ (M) = 5.23\] in causing concentration-dependent \[Ca^2+^\]~i~ increases in MSMCs. The P2Y~4~-selective agonists, inosine 5′-triphosphate, and UTPγS produced almost identical responses, again showing a slightly reduced efficacy relative to UTP ([Supplementary material online, *Figure S1B*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq249/DC1)). The P2Y~6~-selective agonist PSB0474 failed to cause any Ca^2+^ signals, while the P2Y~6~-selective antagonist MRS2578 (10 µM) had no significant effect on the UTP-mediated \[Ca^2+^\]~i~ response ([Supplementary material online, *Figure S1C*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq249/DC1)).

Since our data suggested that MSMCs express a mixed P2Y~2~/P2Y~4~-receptor population, we applied an siRNA approach specifically to deplete the expression of these P2Y-receptor subtypes individually. The effectiveness of siRNA constructs to suppress P2Y~2~- and P2Y~4~-receptor mRNAs was determined using real-time reverse transcription-polymerase chain reactions (RT-PCR) (see Section 2.6) in rat aortic smooth muscle cells 48 h after nucleofection with siRNA constructs targeting P2Y~2~- or P2Y~4~-receptor mRNAs or a NC (non-targeting) siRNA. Data show that nucleofection with NC siRNA had no effect on P2Y~2~ or P2Y~4~ signals (data not shown), while in the presence of anti-P2Y~2~ siRNA, mean P2Y~2~ cycle threshold values were suppressed (Δ*C*~T~ = −2.0, relative to NC siRNA-transfected samples), with no effect on the P2Y~4~ signal (*Figure [2](#CVQ249F2){ref-type="fig"}A*). Conversely, anti-P2Y~4~ siRNA suppressed mean cycle threshold values for P2Y~4~ (Δ*C*~T~ = −3.4), but was without effect on P2Y~2~ signals. Neither P2Y-targeting siRNA altered β-actin mRNA levels significantly (data not shown). Collectively, these data suggest that ≥75% and ≥90% P2Y mRNA transcripts are selectively depleted following transfection of rat vascular smooth muscle with anti-P2Y~2~ or anti-P2Y~4~ siRNAs, respectively. The contributions P2Y~2~- and P2Y~4~-receptors play in UTP-mediated PLC signalling were determined in MSMCs co-transfected with eGFP-PH and NC, anti-P2Y~2~ or anti-P2Y~4~ siRNAs. NC siRNA nucleofection had no significant effect on the magnitude and profile of UTP-stimulated responses in MSMCs (data not shown). UTP-induced eGFP-PH translocation was virtually ablated in MSMCs treated with anti-P2Y~2~ siRNA, whereas anti-P2Y~4~ siRNA treatment was without effect (*Figure [2](#CVQ249F2){ref-type="fig"}C--E*). Furthermore, responses to endothelin-1 were also unaltered following P2Y~2~-depletion (*Figure [2](#CVQ249F2){ref-type="fig"}C*). Collectively, these data strongly suggest that in cultured MSMCs, UTP-mediated signalling via PLC is mediated primarily and perhaps exclusively by P2Y~2~-receptors. Figure 2Dissecting the P2Y~2~/P2Y~4~-receptor dependency of UTP signalling. (*A*) Real-time PCR data showing changes in cycle threshold (Δ*C*~T~) values for P2Y~2~ or P2Y~4~ transcripts, relative to negative-control (NC) and untransfected cells, following transfection with 100 nM of anti-P2Y~2~ or anti-P2Y~4~ receptor siRNAs. Data shown are means ± SEM for *n* = 6 experiments (in triplicate) undertaken in cell preparations from six separate animals. Representative traces (*B*--*D*) and cumulative data (*E*) showing affects of NC (*B*), anti-P2Y~2~ (*C*), or anti-P2Y~4~ (*D*) siRNAs on UTP-stimulated (10 or 100 µM) IP~3~ signals. Data expressed as means ± SEM for *n* = 8--10 cells from cell preparations produced from four or more separate animals. Statistical significance is indicated as asterisk \*\**P* \< 0.01 vs. NC siRNA (one-way ANOVA, Dunnett\'s *post hoc* test).

3.3. Desensitization and resensitization of UTP-signalling in isolated MSMC {#s3c}
---------------------------------------------------------------------------

Time-courses of desensitization/resensitization of receptor--PLC signalling in response to UTP were assessed using similar protocols as those described above for myography experiments, however shorter agonist applications at lower concentrations (*R*~1~/*R*~2~ 10 µM UTP, 30 s; *R*~max~ 100 µM UTP, 30 s) were sufficient to induce significant desensitization (*Figure [3](#CVQ249F3){ref-type="fig"}*). Comparison of UTP-induced changes in IP~3~ (eGFP-PH translocation) and \[Ca^2+^\]~i~ (Fluo4), before (*R*~1~) and after (*R*~2~) the desensitizing UTP (*R*~max~) challenge resulted in a 64% decrease for \[Ca^2+^\]~i~ and 84% decrease for IP~3~ in *R*~2~ vs. *R*~1~ measured 2 and 3 min after *R*~max~ challenge, respectively (*Figure [3](#CVQ249F3){ref-type="fig"}A, C,* and *E*). Prolonging the inter-*R*~max~/*R*~2~ washout period revealed a time-dependent resensitization of UTP-stimulated IP~3~ and \[Ca^2+^\]~i~ responses (*Figure [3](#CVQ249F3){ref-type="fig"}B, D,* and *E*), with essentially complete recovery of UTP-stimulated IP~3~ and \[Ca^2+^\]~i~ responses after 15 and 10 min, respectively (*Figure [3](#CVQ249F3){ref-type="fig"}E*). Figure 3Time-course of UTP-induced P2Y~2~-receptor desensitization. MSMCs were transfected with eGFP-PH (0.5 µg), or loaded with Fluo4 and subjected to the following desensitization protocol: cells were challenged with UTP (*R*~1~, 10 µM, 30 s) 5 min before a desensitizing UTP concentration (*R*~max~ = 100 µM for 30 s), and again after a variable washout period (2, 3, 5, 10, or 15 min) (*R*~2~, 10 µM, 30 s). Representative traces and images from single cells either expressing eGFP-PH (*A* and *B*) or loaded with Fluo4 (*C* and *D*) with either a 3 (*A* and *C*), 10 (*B*), or 15 min (*D*) wash period are shown. P2Y~2~ receptor desensitization was determined as the relative (%) change in *R*~2~ response compared with *R*~1~ for both eGFP-PH and Fluo4 signals. (*E*) Cumulative data are presented as means ± SEM for five to nine cells (eGFP-PH), or 21--45 cells (Fluo4) at each time-point. MSMCs used were generated from preparations from three or more different animals.

3.4. GRK isoenzymic dependency of P2Y-receptor desensitization in MSMCs {#s3d}
-----------------------------------------------------------------------

To determine whether endogenous GRKs regulate UTP signalling in MSMCs, individual GRK isoenzymes were inhibited using catalytically inactive, dominant-negative mutant GRKs. MSMCs were co-transfected with eGFP-PH (0.5 µg) together with pcDNA3 (control), ^D110A,K220R^ GRK2, ^D110A,K220R^GRK3, ^K215R^GRK5, or ^K215R^GRK6 (0.5 µg).^[@CVQ249C14]^ When subjected to the previously described desensitization protocol (with 5 min washes between *R*~1~/*R*~max~/*R*~2~ agonist additions), MSMCs transfected with pcDNA3, ^D110A,K220R^GRK3, ^K215R^GRK5, or ^K215R^GRK6 displayed similar reductions in *R*~2~ responses (∼70%) compared with *R*~1~, comparable to responses observed in non-transfected cells (*Figure [4](#CVQ249F4){ref-type="fig"}*). However, the presence of ^D110A,K220R^GRK2 significantly attenuated reductions in the *R*~2~ response when compared with *R*~1~ (*Figure [4](#CVQ249F4){ref-type="fig"}B* and *F*), suggesting that endogenous GRK2 activity plays a significant role in regulating UTP-stimulated P2Y-receptor-mediated PLC/Ca^2+^ signalling. Figure 4GRK2 inhibition decreases P2Y~2~-receptor desensitization induced by UTP. MSMCs were co-transfected with 0.5 µg eGFP-PH and either pcDNA3 (control), ^D110A,K220R^GRK2, ^D110A,K220R^GRK3, ^K215R^GRK5, or ^K215R^GRK6 (0.5 µg). Cells were subjected to the standard *R*~1~/*R*~max~/*R*~2~ protocol (see Section 2). Representative traces show IP~3~ changes in cells transfected with pcDNA3 (*A*), ^D110A,K220R^GRK2 (*B*), ^D110A,K220R^GRK3 (*C*), ^K215R^GRK5 (*D*), or ^K215R^GRK6 (*E*). P2Y receptor desensitization was determined as the relative (%) change in *R*~2~ response compared with *R*~1~. (*F*) Cumulative data are presented as means ± SEM from 13--19 cells from MSMC preparations from four or more different animals. Statistical significance is indicated as asterisk \*\**P* \< 0.01 vs. vector-transfected MSMCs (one-way ANOVA; Dunnett\'s *post hoc* test).

To corroborate these findings, we applied a previously validated siRNA that specifically depletes endogenous GRK2 (by ≥75%) without altering the expression of non-targeted GRKs.^[@CVQ249C14]^ MSMCs were co-transfected with eGFP-PH (0.5 µg) and either 10 nM anti-GRK2 or NC siRNAs and 48 h later subjected to the standard *R*~1~/*R*~max~/*R*~2~ desensitization protocol (*Figure [5](#CVQ249F5){ref-type="fig"}A* and *B*). In agreement with our data from ^D110A,K220R^GRK2 co-transfections, siRNA-induced depletion of GRK2 attenuated the decrease in *R*~2~ (relative to *R*~1~) caused by *R*~max~ UTP-addition (*Figure [5](#CVQ249F5){ref-type="fig"}B* and *C*). This was most striking for the eGFP-PH/IP~3~ response (*R*~2~/*R*~1~ (%), negative control siRNA, 32 ± 8; anti-GRK2 siRNA, 71 ± 7; *P* \< 0.05; data are means ± SEM). Taken together, these findings strongly suggest that GRK2 is a key mediator of UTP-induced P2Y~2~ receptor desensitization. Figure 5Depletion of endogenous GRK2 attenuates P2Y~2~-receptor desensitization. MSMCs were nucleofected with 0.5 µg eGFP-PH and either negative-control (NC) or anti-GRK2 (10 nM) siRNAs. Cells were loaded with Fura-Red and subjected to the standard *R*~1~/*R*~max~/*R*~2~ desensitization protocol (see Section 2). Representative traces are shown for single cells transfected with NC siRNA (*A*) or anti-GRK2 siRNA (*B*). P2Y receptor desensitization was determined as the relative (%) change in *R*~2~ response compared with *R*~1~. Cumulative data (*C*) show means ± SEM from 8 to 15 cells from MSMCs prepared from more than four separate animals. Statistical significance is indicated as \**P* \< 0.01 vs. NC siRNA-treated MSMCs (one-way ANOVA; Dunnett\'s *post hoc* test).

3.5. Arrestin dependency of P2Y~2~-receptor desensitization in MSMCs {#s3e}
--------------------------------------------------------------------

To examine the potential role that arrestin proteins play in regulating P2Y~2~-receptor signalling, we utilized an siRNA approach to selectively deplete endogenous arrestin2/3 expression. MSMCs were transfected with anti-arrestin2, anti-arrestin3, or NC siRNAs (100 nM) 48 h prior to cell lysis and immunoblotting. Substantial arrestin depletion (\>70% for arrestin2 and arrestin3) was observed at this time-point, and both arrestin2- and arrestin3-targeted siRNAs appeared to be highly selective for their respective targets (*Figure [6](#CVQ249F6){ref-type="fig"}A* and *B*). To determine the effects of arrestin depletion on the desensitization of UTP-stimulated PLC signalling, MSMCs were co-transfected with eGFP-PH (0.5 µg) and anti-arrestin2 or anti-arrestin3, before being subjected to the standard *R*~1~/*R*~max~/*R*~2~ desensitization protocol. In the absence or presence of NC siRNA reductions in *R*~2~ relative to *R*~1~ responses of ≥80% for eGFP-PH and ≥70% for \[Ca^2+^\]~i~ signals were observed (*Figure [6](#CVQ249F6){ref-type="fig"}C* and *E*). Selective depletion of arrestin2 markedly reversed UTP-induced decreases in *R*~2~ relative to *R*~1~ IP~3~/Ca^2+^ responses (*Figure [6](#CVQ249F6){ref-type="fig"}E*). Contrastingly, while arrestin3 depletion had a small effect on *R*~2~/*R*~1~ ratios (*Figure [6](#CVQ249F6){ref-type="fig"}E*), this did not achieve statistical significance, suggesting that attenuation of the UTP signal is primarily effected by the arrestin2 isoform. Figure 6Depletion of endogenous arrestin2 attenuates P2Y~2~-receptor desensitization. MSMCs were nucleofected with NC, anti-arrestin2 or anti-arrestin3 siRNAs (100 nM) (see Section 2). After 48 h, cells were lysed and 40 µg of protein loaded for SDS--PAGE separation and immunoblotting. (*A*) Representative immunoblot showing arrestin2 depletion (upper panel), and the same blot is shown after longer exposure to highlight arrestin3 (lower panel, lower band) depletion, shown in: non-transfected cells (lane 1), or cells treated with 100 nM of anti-arrestin2 (lane 2), anti-arrestin3 (lane 3), or NC (lane 4) siRNAs. (*B*) Cumulative densitometric data show mean arrestin expression ± SEM from four animal cell preparations, \*\**P*\<0.01 vs. NC siRNA (one-way ANOVA; Dunnett\'s *post hoc* test). To assess the effects of arrestin depletion on UTP- or ET1-stimulated PLC signalling, MSMCs were nucleofected with 0.5 µg eGFP-PH and with 100 nM of either NC, anti-arrestin2 or anti-arrestin3 siRNAs. Cells were loaded with Fura-Red and subjected to the standard *R*~1~/*R*~max~/*R*~2~ (for UTP) or *R*~1~/*R*~1~ (for ET-1) desensitization protocols (see Section 2). Representative traces from single cells transfected with control siRNA (*C* and *F*), anti-arrestin2 (*D*), or anti-arrestin3 (*G*). Traces (*C*) and (*D*) show UTP responses, while (*F*) and (*G*) show ET-1 responses. Cumulative data are shown as means ± SEM from 5 to 13 cells from preparations from three to four separate animals for UTP- (*E*) and ET1-stimulated cells (*H*). Statistical significance is indicated as \**P* \< 0.05 or \*\**P* \< 0.01 vs. NC siRNA-treated MSMCs (one-way ANOVA; Dunnett\'s *post hoc* test).

Previously we showed that GRK2 regulates endothelin (ET~A~) receptor desensitization,^[@CVQ249C14]^ suggesting that ET~A~Rs are also likely substrates for arrestin recruitment in MSMCs. Consequently, the potential involvement of arrestin proteins in the regulation of ET~A~ receptor signalling was assessed in MSMCs co-transfected with eGFP-PH and either anti-arrestin2 or anti-arrestin3 siRNAs. Here, ET~A~ receptor desensitization was assessed by exposing cells to a short desensitizing pulse of endothelin-1 (50 nM, 30 s, termed *R*~1~) followed by a 10 min wash period and second endothelin-1 challenge (50 nM, 30 s, termed *R*~2~). The extent of receptor desensitization, assessed at the level of IP~3~ or Ca^2+^, was similar in the absence or presence of NC, or anti-arrestin2 siRNAs (*Figure [6](#CVQ249F6){ref-type="fig"}F* and *H*), whereas, in anti-arrestin3 siRNA-transfected MSMCs endothelin-1-induced receptor desensitization was significantly attenuated (*Figure [6](#CVQ249F6){ref-type="fig"}G* and *H*). These data suggest while both P2Y~2~- and ET~A~-receptors are desensitized via a GRK2-dependent mechanism in MSMCs, it is likely that different arrestins are recruited to the desensitized receptor, with P2Y~2~- and ET~A~-receptors preferentially recruiting arrestin2 and arrestin3, respectively.

4.. Discussion {#s4}
==============

The relative importance of different P2 receptor subtypes present in smooth muscle for contraction is complex and delineation of the contributions of specific subtypes complicated by the lack of highly selective agonists/antagonists. Available data suggest that G protein-coupled P2Y~2~, P2Y~4~, and P2Y~6~ receptors, and ionotropic P2X~1~ receptors contribute to nucleotide-mediated contraction.^[@CVQ249C4],[@CVQ249C16]^ Furthermore, evidence from aortic smooth muscle cells suggests that P2Y-receptor mRNA abundance differs between contractile and synthetic phenotypes, with decreases in P2Y~4~/P2Y~6~, and increases in P2Y~2~ mRNA being observed in the synthetic phenotype.^[@CVQ249C17]^ Our pharmacological and siRNA knockdown data indicate that UTP/PLC responses in isolated MSMCs are primarily mediated by P2Y~2~ receptors, which concurs with previous findings that UTP-mediated contractions in mesenteric arteries (\>180 µm) are sensitive to blockade by the P2Y~2~-selective antagonist suramin.^[@CVQ249C16]^ Furthermore, our UTP-stimulated arterial contractile (EC~50~ 28 µM) and MSMC Ca^2+^ (EC~50~ 6 µM) responses are comparable to those reported in small (\>100 µm) mesenteric arteries.^[@CVQ249C16]^

Previous studies have described desensitization of P2Y~2~-receptor responses in several cell backgrounds,^[@CVQ249C8],[@CVQ249C9],[@CVQ249C18],[@CVQ249C19]^ however, few studies have addressed the regulation of native P2Y~2~-receptor responsiveness and none to our knowledge have done so in mesenteric arteries. In human promonocytic U937, astrocytoma 132N1 and epithelial HT-29 cells P2Y~2~-receptor desensitization has been reported to occur rapidly and is enhanced following phorbol ester addition, however in all cases inclusion of PKC inhibitors failed to prevent receptor desensitization.^[@CVQ249C9],[@CVQ249C18]^ Indeed, the observed attenuations of signalling may have been the result of PKC-mediated inhibition of PLC activity.^[@CVQ249C20]^ Interestingly, protein phosphatase inhibitors can attenuate P2Y~2~-receptor resensitization.^[@CVQ249C18]^ Collectively, these findings suggest that P2Y~2~-receptor phosphorylation, by a kinase(s) other than PKC is required for desensitization.^[@CVQ249C18]^ Our preliminary experiments demonstrated that a protocol similar to that utilized to study H~1~ histamine-receptor desensitization allows quantitative assessment of the desensitization of MSMC responses to UTP.^[@CVQ249C15]^ By employing a protocol where a sub-maximally effective (∼EC~50~) concentration of agonist is added to cells before (*R*~1~) and after (*R*~2~) a maximal, desensitizing agonist exposure (*R*~max~), attenuations of responsiveness are detected irrespective of P2Y~2~-receptor reserve. Moreover, we have extended this approach and utilized a similar *R*~1~/*R*~max~/*R*~2~ protocol in small, intact mesenteric vessels (∼150 µm diameter) to assess receptor desensitization/resensitization at the level of the UTP-evoked contractile response. Interestingly, our data indicate that UTP-stimulated intact vessel contractions are relatively resistant to desensitization when compared with PLC/Ca^2+^ responses in primary MSMCs. These differences might relate to the differing capacities of intact mesenteric smooth muscle and cultured MSMC preparations to metabolize UTP, and/or *ex vivo* changes in receptor populations and/or post-receptor components. Nevertheless, using comparable protocols, it is possible to assess the time-course of receptor desensitization/resensitization with respect to both UTP-stimulated contractile and signalling responses in tissue/cell preparations.

Since GRK proteins are known to regulate the signalling of other PLC-coupled GPCRs expressed in MSMCs,^[@CVQ249C14],[@CVQ249C21],[@CVQ249C22]^ we initially utilized dominant-negative (kinase-dead) GRK mutants to disrupt P2Y~2~-receptor/GRK isoenzyme-specific interactions in an attempt to attenuate or prevent the reduction in receptor responsiveness observed on re-addition of UTP subsequent to a desensitizing pulse of this agonist. The ^D110A,K220R^GRK2 construct, which has been mutated to prevent both kinase activity and Gα~q/11~-binding,^[@CVQ249C20]^ markedly attenuated P2Y~2~-receptor desensitization. Conversely, over-expression of ^D110A,K220R^GRK3, ^K215R^GRK5, or ^K215R^GRK6 mutants affected neither the extent of desensitization, nor the time-course of recovery of P2Y~2~-receptor responsiveness to UTP. To complement our findings (and address any potential criticisms associated with the recombinant over-expression of GRK mutants), we also depleted (\>75%) endogenous GRK2 expression in MSMCs using isoenzyme-specific siRNAs, producing near-identical data to those obtained using the ^D110A,K220R^GRK2 construct.

Together these findings indicate that GRK2 is a key endogenous GRK isoenzyme initiating P2Y~2~-receptor desensitization in MSMCs, with either GRK2 knockdown or disruption of the normal GRK2-receptor interaction causing an ∼60% attenuation of agonist-stimulated P2Y~2~-receptor desensitization; a figure only ∼15% less than that achievable after full receptor resensitization. It is possible that GRK2 is the only kinase involved in initiating P2Y~2~-receptor desensitization and that the observed partial effects arise because the experimental ablations of GRK2 activity are incompletely effective. On the other hand, while a predominant GRK isoenzyme can often be identified as being responsible for initiating receptor desensitization it is rare for this to be the only protein kinase involved.^[@CVQ249C23],[@CVQ249C24]^ Therefore, other (minor) mechanisms may yet be shown to be involved in regulating P2Y~2~-receptor responsiveness in MSMCs.

GRK2 has previously been reported to be the key GRK isoenzyme regulating angiotensin II type 1 (AT~1~),^[@CVQ249C25]^ α~1D~-adrenergic,^[@CVQ249C22]^ and ET~A~^[@CVQ249C14]^ receptor-mediated contractile responses. The finding that GRK2 is also key to the regulation of P2Y~2~-receptor signalling further emphasizes the importance of this GRK isoenzyme in Gα~q/11~/PLC-coupled receptor regulation in arterial smooth muscle.

GRK-mediated phosphorylation often leads to arrestin recruitment to the receptor, promoting internalization, receptor recycling, and/or downregulation.^[@CVQ249C10],[@CVQ249C11]^ When expressed in HEK293 cells, P2Y~2~-receptors recruit both exogenous arrestin2 and arrestin3,^[@CVQ249C26]^ however, while suggestive that P2Y~2~ receptors can interact with arrestin proteins, these studies are not necessarily predictive of how, or if, these receptors are regulated in native tissues. Here, we utilized an RNAi strategy to suppress individual arrestin isoform expression to delineate for the first time their role in P2Y~2~ receptor regulation in resistance artery smooth muscle. Our data indicate a high degree of isoform-selective arrestin interaction with P2Y~2~, with siRNA-mediated depletion of arrestin2 almost completely attenuating UTP-stimulated P2Y~2~-receptor desensitization. Conversely, knockdown of arrestin3 was without effect on P2Y~2~ signalling. We also assessed whether another important vasoconstrictor GPCR also differentially recruits arrestin2/3 isoforms, and showed that ET~A~-receptor responses are attenuated by arrestin3, but not arrestin2 knockdown. Moreover, we recently showed that GRK2 is also a critical kinase involved in ET~A~-receptor desensitization.^[@CVQ249C14]^ Consequently, our findings clearly demonstrate that phosphorylation by a common GRK isoenzyme can lead to contrasting arrestin isoform recruitment. A likely explanation that deserves future investigation is that the pattern of GRK2-mediated P2Y~2~- and ET~A~-receptor phosphorylation differs sufficiently to promote differential recruitment of arrestins.

Finally, the potential importance of arrestin recruitment in vascular disease has been highlighted by two recent studies. Data from arrestin knockout mice reveal a role for arrestins in the regulation of vascular smooth muscle migration and proliferation during atherosclerosis and neointimal hyperplasia,^[@CVQ249C27]^ while arrestin3 regulates angiotensin II-stimulated, ERK-mediated aortic smooth muscle proliferation.^[@CVQ249C28]^ Since our new findings highlight a selective arrestin regulation of ET~A~- and P2Y~2~-receptors, it is likely that differential recruitment of arrestins to phosphorylated GPCRs has the potential to determine physiological and pathophysiological signalling outcomes activated by UTP and ET-1.
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